Studies of White Blood Cells Derived From HHT Patients

StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study description expanded, about 139 words
    • Publications: 2 to 4
    v4
  2. Trial status: Recruiting to Active, Not Recruiting
    • Primary and study completion dates: Oct 2026
    • Site details revised
    • Eligibility criteria expanded, about 1 word
    v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an inherited vascular disease that leads to the development of dilated and fragile blood vessels. The study goal is to culture white blood cells that express the proteins mutated in HHT and examine in the laboratory to explain aspects of the HHT disease phenotype.
Trial Details
NCT Number NCT00230633
Lead Sponsor Imperial College London
Collaborators: British Heart Foundation
Conditions
(from sponsor)		 Telangiectasia, Hereditary Hemorrhagic
Related terms Telangiectasia, Hereditary Hemorrhagic, Telangiectasis
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov